293 filings
Page 2 of 15
8-K
t92 b0fnd
28 Dec 22
Other Events
8:10am
8-K
2knzrmp4zx78b2nwavt
22 Dec 22
Other Events
8:17am
8-K
suyls1e2cj3w6aga aa3
14 Nov 22
Acasti Pharma Reports Second Quarter 2023 Operational Results
7:15am
8-K
o46ial
30 Sep 22
Acasti Announces Court Dismissal of Stockholder Litigation
4:08pm
8-K
0rbk9aql6 pz5t
29 Sep 22
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
9:26am
8-K
0uwn570ymp1izw2dm191
11 Aug 22
Acasti Pharma Reports First Quarter 2023 Operational Results
7:05am
8-K
z64ko0271t25l
29 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
qnlt9v tj
21 Jun 22
Results of Operations and Financial Condition
8:10am
8-K
8nl6ew1fj7b64p8
18 May 22
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints
7:37am
8-K
e1gzp2rb95t
25 Mar 22
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
7:36am
8-K
zxahfjfkzdjfr4m156
14 Feb 22
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
7:10am
8-K
1nxjejeq10i5oy6 zae
2 Dec 21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
7:17am
8-K
q8xhh3m 7jef2d
15 Nov 21
Acasti Pharma Announces Annual Stock Option Grants
12:00am
8-K
e2r7v
10 Nov 21
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022
7:09am
8-K/A
fcbxf1df
5 Nov 21
Financial Statements and Exhibits
4:07pm
8-K
s0u2qn
22 Sep 21
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
8:30am
8-K
pmo3lyihzcj37i7
9 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:19pm
8-K
tre7v8w2hlj bj7lkjpw
27 Aug 21
Completion of Acquisition or Disposition of Assets
8:47am
8-K
6e0ung7dbkad bt6n5
12 Aug 21
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
10:57am
8-K
su36wttwv 0s1hw
23 Jul 21
Other Events
8:43am